26 . 01 .2023
Press release
Galderma announces the launch of FACE by Galderma™ – a game-changing augmented reality solution helping healthcare professionals grow their activity and improve patient satisfaction
23 . 01 .2023
Press release
Galderma expands footprint with new Global Capability Center in Barcelona to support global growth
20 . 01 .2023
Press release
IMCAS 2023: Galderma to share latest data demonstrating high aesthetic improvement and patient satisfaction across its innovative portfolio
13 . 10 .2022
Press release
Galderma announces intention to expand manufacturing and innovation footprint in Asia-Pacific
16 . 09 .2022
Press release
Galderma debuts the Sensitive Skincare Faculty, a global expert group to improve understanding and management of sensitive skin
06 . 09 .2022
Press release
Galderma showcases its continued commitment to innovation in dermatology with new data to be presented at 2022 EADV congress
25 . 08 .2022
Press release
Galderma delivers strong H1 2022 results and continued innovation across its leading dermatology portfolio
22 . 06 .2022
Press release
Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis
10 . 06 .2022
Press release
Galderma announces positive results in two phase III studies for a novel liquid formulation botulinumtoxinA (RelabotulinumtoxinA) for the treatment of glabellar lines (frown) and lateral canthal lines (crow’s feet)
31 . 05 .2022
Press release
Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022